The present disclosure relates generally to medical treatment systems, and more particularly, to apparatuses, systems, and methods for treating tissue sites using reduced pressure.
Depending on the medical circumstances, reduced pressure may be used for, among other things, reduced-pressure therapy to encourage granulation at a tissue site or for draining fluids at a tissue site. As used herein, unless otherwise indicated, “or” does not require mutual exclusivity. Both reduced-pressure therapy and drainage with reduced pressure often involve manifolding, or distributing, reduced pressure to the tissue site.
According to a non-limiting, illustrative embodiment, a dressing for distributing reduced pressure to a tissue site includes a plurality of liquid-impermeable layers that are stacked and a plurality of spacers disposed at least partially between adjacent liquid-impermeable layers. The plurality of liquid-impermeable layers are fenestrated. The plurality of spacers and plurality of liquid-impermeable layers form a plurality of flow paths for allowing fluid flow under reduced pressure. Adjacent layers of the plurality of liquid-impermeable layers may be stacked without foam between at least a majority of coextensive surfaces.
According to another non-limiting, illustrative embodiment, a system for distributing reduced pressure to a tissue site includes a reduced-pressure source, a reduced-pressure delivery conduit, and a reduced-pressure dressing. The reduced-pressure delivery conduit fluidly couples the reduced-pressure source and the reduced-pressure dressing. The reduced-pressure dressing includes a plurality of liquid-impermeable layers that are stacked and a plurality of spacers disposed at least partially between liquid-impermeable layers. The plurality of liquid-impermeable layers are fenestrated. The plurality of spacers and plurality of liquid-impermeable layers form a plurality of flow paths for allowing fluid flow under reduced pressure. Adjacent layers of the plurality of liquid-impermeable layers may be stacked without foam between at least a majority of coextensive surfaces.
According to another non-limiting, illustrative embodiment, a method of manufacturing a dressing for distributing reduced pressure to a tissue site includes the steps of: providing a plurality of liquid-impermeable layers, stacking the plurality of liquid-impermeable layers, and forming a plurality of spacers disposed at least partially between adjacent liquid-impermeable layers. The plurality of liquid-impermeable layers are fenestrated. The plurality of spacers and plurality of liquid-impermeable layers form a plurality of flow paths for allowing fluid flow under reduced pressure. Adjacent layers of the plurality of liquid-impermeable layers are stacked without foam between at least a majority of coextensive surfaces.
According to another non-limiting, illustrative embodiment, a method for delivering reduced pressure to a tissue site includes the steps of: providing a reduced-pressure dressing, deploying the reduced-pressure dressing adjacent to the tissue site, fluidly coupling a reduced-pressure source to the reduced-pressure dressing, and activating the reduced-pressure source. The reduced-pressure dressing includes a plurality of liquid-impermeable layers that are stacked and a plurality of spacers disposed at least partially between adjacent liquid-impermeable layers. The plurality of liquid-impermeable layers are fenestrated. The plurality of spacers and plurality of liquid-impermeable layers form a plurality of flow paths for allowing fluid flow under reduced pressure. Adjacent layers of the plurality of liquid-impermeable layers may be stacked without foam between at least a majority of coextensive surfaces.
Other features and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.
In the following detailed description of the non-limiting, illustrative embodiments, reference is made to the accompanying drawings that form a part hereof. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the illustrative embodiments are defined only by the appended claims.
Referring now to
As shown, the abdominal treatment device 104 is disposed within the abdominal cavity 102 of the patient to treat the tissue site 106. The abdominal treatment device 104 is supported by the abdominal contents 108. The abdominal contents 108 make up a surface on which the abdominal treatment device 104 is placed. A portion 110 of the abdominal treatment device 104 may be placed in or proximate to a first paracolic gutter 112, and another portion 114 may be placed in or proximate to a second paracolic gutter 116.
The abdominal treatment device 104 is formed with a plurality of liquid-impermeable layers 117, e.g., a first liquid-impermeable layer 118 and a second liquid-impermeable layer 120. The plurality of liquid-impermeable layers 117, e.g., layers 118, 120, are formed with fenestrations 122, 124, respectively. “Liquid impermeable” with respect to “liquid-impermeable layers” means that the layers are formed with a liquid-impermeable material. Thus, although formed with a liquid-impermeable material, the layer may be liquid permeable when fenestrated, but nonetheless is referred to as a liquid-impermeable layer. The fenestrations 122, 124 may take any shape, e.g., circular apertures, rectangular openings, or polygons. The fenestrations 122, 124 are presented in this illustrative embodiment as slits, or linear cuts. Not every layer need be fenestrated. The abdominal treatment device 104 has a first side 105 and a second, tissue-facing side 107. The abdominal treatment device 104 is typically symmetrical such that the sides 105, 107 are same. Reference to different sides, however, is made for explanation purposes.
A manifold 126, or manifold pad, distributes reduced pressure to the abdominal treatment device 104. A sealing member 128 provides a fluid seal over the abdominal cavity 102. One or more skin closure devices may be placed on a patient's epidermis 130.
A reduced-pressure connector subsystem 132 may be used to fluidly couple the abdominal treatment device 104 to a reduced-pressure delivery conduit 134. The reduced-pressure connector subsystem 132 may include a reduced-pressure connector 136, or interface, and the manifold 126. Alternatively, the reduced-pressure connector subsystem 132 may be an in situ connector (not shown) on the abdominal treatment device 104 or any other device for supplying reduced pressure to the abdominal treatment device 104. The reduced-pressure delivery conduit 134 is fluidly coupled to a reduced-pressure source 137. In one illustrative embodiment, reduced pressure is delivered to the abdominal treatment device 104 through the manifold 126 which receives reduced pressure through the reduced-pressure connector 136, which is coupled to the reduced-pressure delivery conduit 134. The reduced-pressure source 137 delivers reduced pressure to the reduced-pressure delivery conduit 134.
The reduced pressure may be applied to the tissue site 106 to help promote removal of ascites, exudates, or other fluids from the tissue site 106. In some instances, reduced pressure may be applied to stimulate the growth of additional tissue. In some instances, only fluid removal may be desired. As used herein, “reduced pressure” generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure at the tissue site.
The manifold 126 is shown adjacent to the abdominal treatment device 104. The manifold 126 may take many forms. The term “manifold” as used herein generally refers to a substance or structure that is provided to assist in applying reduced pressure to, delivering fluids to, or removing fluids from the tissue site 106 directly or via the abdominal treatment device 104. The manifold 126 typically includes a plurality of flow channels or pathways that distribute the fluids provided to and removed from the tissue site 106 around the manifold 126 and through the abdominal treatment device 104. In one illustrative embodiment, the flow channels or pathways are interconnected to improve distribution of fluids provided or removed. The manifold 126 may be a biocompatible material that is capable of being placed in contact with the tissue site 106 and distributing reduced pressure to the tissue site 106 or abdominal treatment device 104. Examples of manifold 126 may include, without limitation, devices that have structural elements arranged to form flow channels, cellular foam, such as open-cell foam, porous tissue collections, liquids, gels and foams that include or cure to include flow channels. The manifold 126 may be porous and may be made from foam, gauze, felted mat, or any other material suited to a particular biological application. In one embodiment, the manifold 126 is a porous foam and includes a plurality of interconnected cells or pores that act as flow channels. The porous foam may be a polyurethane, open-cell, reticulated foam, such as a GranuFoam® material manufactured by Kinetic Concepts, Incorporated of San Antonio, Tex. Other embodiments may include “closed cells.” In some situations, the manifold 126 may also be used to distribute fluids, such as medications, antibacterials, growth factors, and various solutions. Other layers may be included in or on the manifold 126, such as absorptive materials, wicking materials, hydrophobic materials, and hydrophilic materials.
The sealing member 128 is placed over the abdominal cavity 102 and provides a fluid seal. As used herein, “fluid seal,” or “seal,” means a seal adequate to maintain reduced pressure at a desired site given the particular reduced-pressure source or subsystem involved. The sealing member 128 may be a cover, or drape, that is used to secure the manifold 126 on a portion of the abdominal treatment device 104. The sealing member 128 may be impermeable or semi-permeable. The sealing member 128 is capable of maintaining reduced pressure at the tissue site 106 or other desired location after installation of the sealing member 128 over the abdominal cavity 102 and particularly an abdominal cavity opening 140. The sealing member 128 may be a flexible over-drape or film formed from a silicone-based compound, acrylic, hydrogel or hydrogel-forming material, polyurethane, polymer film, or any other biocompatible material that includes the impermeability or permeability characteristics as desired for applying reduced pressure to the tissue site 106.
The sealing member 128 may further include an attachment device 142 to couple the sealing member 128 to the patient's epidermis 130. The attachment device 142 may take many forms. For example, the attachment device 142 may be an adhesive layer 144 that may be positioned along a perimeter of the sealing member 128 or any portion of the sealing member 128 to provide, directly or indirectly, a fluid seal with the patient's epidermis 130. The adhesive layer 144 may also be pre-applied to the sealing member 128 and covered with a releasable backing, or member (not shown), that is removed at the time of application.
The reduced-pressure connector 136 may be, as one example, a port or connector, which permits the passage of fluid from the manifold 126 to the reduced-pressure delivery conduit 134 and vice versa. For example, fluid collected from the tissue site 106 using the manifold 126 and the abdominal treatment device 104 may enter the reduced-pressure delivery conduit 134 via the reduced-pressure connector 136. In another embodiment, the system 100 may omit the reduced-pressure connector 136 and the reduced-pressure delivery conduit 134 may be inserted directly into the sealing member 128 and into the manifold 126. The reduced-pressure delivery conduit 134 may be a medical conduit or tubing or any other means for transportating a reduced pressure and fluid. The reduced-pressure delivery conduit 134 may be a multi-lumen member for readily delivering reduced pressure and removing fluids. In one embodiment, the reduced-pressure delivery conduit 134 is a two-lumen conduit with one lumen for reduced pressure and liquid transport and one lumen for communicating pressure to a pressure sensor.
Reduced pressure is generated and supplied to the reduced-pressure delivery conduit 134 by the reduced-pressure source 137. A wide range of reduced pressures may be generated or supplied by the reduced-pressure source 137. In one illustrative embodiment, the reduced pressure is in the range of −50 to −300 mm Hg and in another illustrative embodiment, the range may include −100 mm Hg to −200 mm Hg. The pressure may be, for example, −100, −110, −120, −125, −130, −140, −150, −160, −170, −180, −190, or −200 mm Hg. In one illustrative embodiment, the reduced-pressure source 137 includes preset selectors for −100 mm Hg, −125 mm Hg, and −150 mm Hg. The reduced-pressure source 137 may also include a number of alarms, such as a blockage alarm, a leakage alarm, canister full alarm, or a battery-low alarm. The reduced-pressure source 137 may be a portable source, wall source, or other unit for abdominal cavities or other tissue sites. The reduced-pressure source 137 may selectively deliver a constant pressure, varied pressure, intermittent pressure, or continuous pressure. The fluid removed from the abdominal cavity 102 through the reduced-pressure delivery conduit 134 could be as much as 5 L or more per day depending on the circumstances. A fluid reservoir is typically associated with the reduced-pressure source 137 for receiving fluids.
A number of different devices, e.g., device 146, may be added to a portion of the reduced-pressure delivery conduit 134. For example, the device 146 may be a fluid reservoir, or canister collection member, a pressure-feedback device, a volume detection system, a blood detection system, an infection detection system, a filter, a port with a filter, a flow monitoring system, a temperature monitoring system, etc. Multiple devices 146 may be included. Some of these devices, e.g., the fluid collection member, may be formed integrally to the reduced-pressure source 137.
Referring now primarily to
The plurality of liquid-impermeable layers 202 may include fenestrations 203, which may be formed with any shape and size. The fenestrations 203 allow the egress of reduced pressure and the ingress of fluids. The plurality of liquid-impermeable layers 202 may be formed from numerous materials including the materials used for the sealing member 128 of
The plurality of spacers 208 may be disposed (including formed or positioned) at least partially between adjacent members of the plurality of liquid-impermeable layers 202. “Partially” means to some extent or degree. The plurality of spacers 208 may be formed by portions of the impermeable layers themselves bonded to hold portions of adjacent layers with a relative displacement or may be formed by the layers being folded or in other ways as shown and described herein. Reference to spacers “between” layers means the portions displacing the layers or portions of the layers are at least partially located between the exterior of adjacent layers. For example, a fold has a curved portions between the exteriors of two layers that may be formed from a single layer of material. Thus, the spacer may be said to be between layers even when formed by portions of the layers. The plurality of spacers 208 provide areas of separation between adjacent members of the plurality of liquid-impermeable layers 202 and thereby help create a plurality of flow paths 210. The figures are not to scale, and it should be understood that the flow paths 210 may be much more dense than shown. For example, the flow paths 210 may be only one millimeter apart, two millimeters apart, three millimeters apart, four millimeters a part, or another dimension.
The plurality of spacers 208 and plurality of liquid-impermeable layers 202 form the plurality of flow paths 210 for allowing fluid flow under reduced pressure or positive pressure. Adjacent layers of the plurality of liquid-impermeable layers 202 are typically stacked. “Stacked” generally means disposing or forming layers to be adjacent. In some embodiments, foam or other material with flow paths may be included between the liquid-impermeable layers 202. For example, the first liquid-impermeable layer 204 and the second liquid-impermeable layer 206 may share an area A1 and the foam may have an area A2 that is in the range of 0% to 50% of A1 and often includes no foam (i.e., 0% A1).
The plurality of spacers 208 may be formed in numerous ways including by forming a plurality of bonds 212 at a plurality of bond sites 214. The plurality of bonds 212 may be formed using any known technique, including without limitation welding (e.g., ultrasonic or RF welding), chemical bonding, adhesives, or cements. The plurality of bond sites 214 may be random or may have a spaced pattern. The plurality of bonds 212 may have a longitudinal dimension, a lateral dimension, and a vertical dimension (for the orientation shown). The plurality of bonds 212 may have an aspect ratio (longitudinal dimension/lateral dimension) greater than 3, or greater than 6, or greater still. The plurality of bonds 212 may also be circular in nature or any other shape.
Referring now primarily to
Referring now primarily to
Referring now primarily to
Referring now primarily to
The manifold member 302 is placed adjacent to the tissue site 304 and then is covered with a sealing member 312. An attachment device 314 may be used to help provide a fluid seal over the tissue site 304. A connector subsystem 316 may fluidly couple a reduced-pressure delivery conduit 318 and the manifold member 302. The reduced-pressure delivery conduit 318 is also fluidly coupled to a reduced-pressure source 320. A device 322 may be fluidly coupled or otherwise associated with the reduced-pressure delivery conduit 318.
The device 322 is the same or analogous to the device 146 of
In operation, the manifold member 302 is placed adjacent to the tissue site 304. The sealing member 312 is applied over the tissue site 304 and a fluid seal is thereby formed. If not already applied, the reduced-pressure connector subsystem 316 is applied to the sealing member 312. If not already installed, the reduced-pressure delivery conduit 318 is fluidly coupled to the reduced-pressure connector subsystem 316 and to the reduced-pressure source 320. The reduced-pressure source 320 is activated. The reduced pressure is communicated to the manifold member 302 and causes reduced pressure to be delivered to the tissue site 304 through a plurality of flow paths (see flow paths 210 in
Referring now primarily to
Referring now primarily to
A fold 510 has a curved portion 511 with a radius 512. The dressing 500 may have a plurality of folds, such as fold 510. The folds, e.g., 510, serve as spacers. The radius 512 is relatively larger when thicker materials or more rigid materials are used for the plurality of liquid-impermeable layers 502. The radius 512 forms a micro-channel 520, which may be one of a plurality of flow paths 518. The first liquid-impermeable layer 504 may be formed with enlarged portions, e.g., enlarged portions 514 and 516 that help define the plurality of flow paths 518. The radius 512 may also form or help form one of the flow paths 518. The flow paths 518 may be formed by a plurality of enlarged portions, e.g., enlarged portions 514, 516, or a plurality of folds, e.g., the fold 510 or both.
Referring now primarily to
The dressing 600 is formed with the two-dimensional flat layer 602, or liquid-impermeable layer 602. The liquid-impermeable layer 602 has fenestrations 604. The fenestrations 604 allow the egress of reduced pressure and the ingress of fluids. The liquid-impermeable layer 602 may be formed from any suitable material, such as those mentioned in connection with the liquid-impermeable layers 118, 120, 204, and 206 of
The dressing 600 is for use with the curved body part 606. The curved body 606 may be any part of a patient that is not flat and that typically has a substantial curvature. Referring now primarily to
Referring now primarily to
Referring primarily now to
Referring now primarily to
The liquid-delivery channel 806 may include a first portion 808. The first portion 808 is part of a first liquid-impermeable layer 810 of the plurality of liquid-impermeable layers 802, but without fenestrations 804. The liquid-delivery channel 806 also includes a second portion 812. The second portion 812 is part of a second liquid-impermeable layer 814 of the plurality of liquid-impermeable layers 802, and again the second liquid-impermeable layer 814 has no fenestrations 804. A channel-forming bond 816 is formed that couples the first portion 808 and the second portion 812 to form a liquid delivery path 818. A liquid aperture 820 may be formed on the first liquid-impermeable layer 810 to facilitate fluidly coupling of a liquid-supply source (not shown) to the liquid-delivery channel 806.
In operation, according to one illustrative embodiment, the dressing 800 is deployed as part of a reduced-pressure treatment system proximate the tissue site to be treated. A reduced-pressure source (not shown) is fluidly coupled to a reduced-pressure aperture 822 to provide reduced pressure to the dressing 800. The reduced pressure pulls fluids into the dressing 800 except for the liquid-delivery channel 806. A fluid-supply source (not shown) is fluidly coupled to the liquid aperture 820. Liquid, e.g., a saline irrigation fluid or medicine, is delivered to the liquid aperture 820. Under the influence of reduced pressure experienced at a peripheral edge 824, liquid delivered to the liquid aperture 820 is urged through the liquid delivery path 818 toward the peripheral edge 824 and exits the liquid delivery channel 806 as suggested by arrows 826 and 828 in
Although the present invention and its advantages have been disclosed in the context of certain illustrative, non-limiting embodiments, it should be understood that various changes, substitutions, permutations, and alterations can be made without departing from the scope of the invention as defined by the appended claims. It will be appreciated that any feature that is described in connection to any one embodiment may also be applicable to any other embodiment.
It will be understood that the benefits and advantages described above may relate to one embodiment or may relate to several embodiments. It will further be understood that reference to ‘an’ item refers to one or more of those items.
The steps of the methods described herein may be carried out in any suitable order, or simultaneously where appropriate.
Where appropriate, aspects of any of the examples described above may be combined with aspects of any of the other examples described to form further examples having comparable or different properties and addressing the same or different problems.
It will be understood that the above description of preferred embodiments is given by way of example only and that various modifications may be made by those skilled in the art. The above specification, examples and data provide a complete description of the structure and use of exemplary embodiments of the invention. Although various embodiments of the invention have been described above with a certain degree of particularity, or with reference to one or more individual embodiments, those skilled in the art could make numerous alterations to the disclosed embodiments without departing from the scope of the claims.
The present invention claims the benefit, under 35 USC §119(e), of the filing of U.S. Provisional Patent Application Ser. No. 61/312,968, entitled “Dressings, Systems, and Methods for Treating a Tissue Site,” filed Mar. 11, 2010, which is incorporated herein by reference for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
1355846 | Rannells | Oct 1920 | A |
2547758 | Keeling | Apr 1951 | A |
2632443 | Lesher | Mar 1953 | A |
2682873 | Evans et al. | Jul 1954 | A |
2910763 | Lauterbach | Nov 1959 | A |
2969057 | Simmons | Jan 1961 | A |
3066672 | Crosby, Jr. et al. | Dec 1962 | A |
3367332 | Groves | Feb 1968 | A |
3520300 | Flower, Jr. | Jul 1970 | A |
3568675 | Harvey | Mar 1971 | A |
3648692 | Wheeler | Mar 1972 | A |
3682180 | McFarlane | Aug 1972 | A |
3826254 | Mellor | Jul 1974 | A |
4080970 | Miller | Mar 1978 | A |
4096853 | Weigand | Jun 1978 | A |
4139004 | Gonzalez, Jr. | Feb 1979 | A |
4165748 | Johnson | Aug 1979 | A |
4184510 | Murry et al. | Jan 1980 | A |
4233969 | Lock et al. | Nov 1980 | A |
4245630 | Lloyd et al. | Jan 1981 | A |
4256109 | Nichols | Mar 1981 | A |
4261363 | Russo | Apr 1981 | A |
4275721 | Olson | Jun 1981 | A |
4284079 | Adair | Aug 1981 | A |
4297995 | Golub | Nov 1981 | A |
4333468 | Geist | Jun 1982 | A |
4373519 | Errede et al. | Feb 1983 | A |
4382441 | Svedman | May 1983 | A |
4392853 | Muto | Jul 1983 | A |
4392858 | George et al. | Jul 1983 | A |
4419097 | Rowland | Dec 1983 | A |
4465485 | Kashmer et al. | Aug 1984 | A |
4475909 | Eisenberg | Oct 1984 | A |
4480638 | Schmid | Nov 1984 | A |
4525166 | Leclerc | Jun 1985 | A |
4525374 | Vaillancourt | Jun 1985 | A |
4540412 | Van Overloop | Sep 1985 | A |
4543100 | Brodsky | Sep 1985 | A |
4548202 | Duncan | Oct 1985 | A |
4551139 | Plaas et al. | Nov 1985 | A |
4569348 | Hasslinger | Feb 1986 | A |
4605399 | Weston et al. | Aug 1986 | A |
4608041 | Nielson | Aug 1986 | A |
4640688 | Hauser | Feb 1987 | A |
4655754 | Richmond et al. | Apr 1987 | A |
4664662 | Webster | May 1987 | A |
4710165 | McNeil et al. | Dec 1987 | A |
4733659 | Edenbaum et al. | Mar 1988 | A |
4743232 | Kruger | May 1988 | A |
4758220 | Sundblom et al. | Jul 1988 | A |
4787888 | Fox | Nov 1988 | A |
4826494 | Richmond et al. | May 1989 | A |
4838883 | Matsuura | Jun 1989 | A |
4840187 | Brazier | Jun 1989 | A |
4863449 | Therriault et al. | Sep 1989 | A |
4872450 | Austad | Oct 1989 | A |
4878901 | Sachse | Nov 1989 | A |
4897081 | Poirier et al. | Jan 1990 | A |
4906233 | Moriuchi et al. | Mar 1990 | A |
4906240 | Reed et al. | Mar 1990 | A |
4919654 | Kalt et al. | Apr 1990 | A |
4941882 | Ward et al. | Jul 1990 | A |
4953565 | Tachibana et al. | Sep 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
4985019 | Michelson | Jan 1991 | A |
5037397 | Kalt et al. | Aug 1991 | A |
5086170 | Luheshi et al. | Feb 1992 | A |
5092858 | Benson et al. | Mar 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5134994 | Say | Aug 1992 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5167613 | Karami et al. | Dec 1992 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5215522 | Page et al. | Jun 1993 | A |
5232453 | Plass et al. | Aug 1993 | A |
5261893 | Zamierowski | Nov 1993 | A |
5278100 | Doan et al. | Jan 1994 | A |
5279550 | Habib et al. | Jan 1994 | A |
5298015 | Komatsuzaki et al. | Mar 1994 | A |
5342376 | Ruff | Aug 1994 | A |
5344415 | DeBusk et al. | Sep 1994 | A |
5358494 | Svedman | Oct 1994 | A |
5437622 | Carion | Aug 1995 | A |
5437651 | Todd et al. | Aug 1995 | A |
5527293 | Zamierowski | Jun 1996 | A |
5549584 | Gross | Aug 1996 | A |
5556375 | Ewall | Sep 1996 | A |
5607388 | Ewall | Mar 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
6071267 | Zamierowski | Jun 2000 | A |
6135116 | Vogel et al. | Oct 2000 | A |
6241747 | Ruff | Jun 2001 | B1 |
6287316 | Agarwal et al. | Sep 2001 | B1 |
6345623 | Heaton et al. | Feb 2002 | B1 |
6488643 | Tumey et al. | Dec 2002 | B1 |
6493568 | Bell et al. | Dec 2002 | B1 |
6553998 | Heaton et al. | Apr 2003 | B2 |
6814079 | Heaton et al. | Nov 2004 | B2 |
7645269 | Zamierowski | Jan 2010 | B2 |
20020077661 | Saadat | Jun 2002 | A1 |
20020115951 | Norstrem et al. | Aug 2002 | A1 |
20020120185 | Johnson | Aug 2002 | A1 |
20020143286 | Tumey | Oct 2002 | A1 |
20060041247 | Petrosenko et al. | Feb 2006 | A1 |
20080243044 | Hunt et al. | Oct 2008 | A1 |
20090227969 | Jaeb et al. | Sep 2009 | A1 |
Number | Date | Country |
---|---|---|
550575 | Aug 1982 | AU |
745271 | Apr 1999 | AU |
755496 | Feb 2002 | AU |
2005436 | Jun 1990 | CA |
26 40 413 | Mar 1978 | DE |
43 06 478 | Sep 1994 | DE |
295 04 378 | Oct 1995 | DE |
0100148 | Feb 1984 | EP |
0117632 | Sep 1984 | EP |
0161865 | Nov 1985 | EP |
0358302 | Mar 1990 | EP |
1018967 | Aug 2004 | EP |
692578 | Jun 1953 | GB |
2 195 255 | Apr 1988 | GB |
2 197 789 | Jun 1988 | GB |
2 220 357 | Jan 1990 | GB |
2 235 877 | Mar 1991 | GB |
2 333 965 | Aug 1999 | GB |
2 329 127 | Aug 2000 | GB |
4129536 | Apr 1992 | JP |
71559 | Apr 2002 | SG |
WO 8002182 | Oct 1980 | WO |
WO 8704626 | Aug 1987 | WO |
WO 9010424 | Sep 1990 | WO |
WO 9309727 | May 1993 | WO |
WO 9420041 | Sep 1994 | WO |
WO 9605873 | Feb 1996 | WO |
WO 9718007 | May 1997 | WO |
WO 9913793 | Mar 1999 | WO |
WO 2004037334 | May 2004 | WO |
WO 2006059893 | Jun 2006 | WO |
WO 2008103625 | Aug 2008 | WO |
Entry |
---|
N.A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of the Soft Tissues,” Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986);pp. 94-96. |
Louis C. Argenta, MD and Michael J. Morykwas, PhD; “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience”; Annals of Plastic Surgery, vol. 38, No. 6, Jun. 1997; pp. 563-576. |
Susan Mendez-Eastmen, RN; “When Wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24. |
James H. Blackburn, II, MD, et al; “Negative-Pressure Dressings as a Bolster for Skin Grafts”; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457. |
John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letter to the Editor, British Journal of Plastic Surgery, 1998, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK. |
S.E. Greer, et al “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin” British Journal of Plastic Surgery (2000), 53, pp. 484-487. |
George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, 31, 1990, pp. 634-639. |
Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80. |
International Search Report for PCT International Application PCT/GB95/01983; Nov. 23, 1995. |
PCT International Search Report for PCT International Application PCT/GB98/02713; Jan. 8, 1999. |
PCT Written Opinion; PCT International Application PCT/GB98/02713; Jun. 8, 1999. |
PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; Jan. 15, 1998 & Apr. 29, 1997. |
PCT Written Opinion, PCT International Application PCT/GB96/02802; Sep. 3, 1997. |
Datillo, Philip P., Jr., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5. |
Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof. |
Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof. |
Yusupov. Yu. N., et al; “Active Wound Drainage”, Vestnik Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof. |
Davydov, Yu. A., et al; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirurgi, Oct. 1988, pp. 48-52, and 8 page English translation thereof. |
Davydov, Yu. A., et al; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof. |
Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63. |
Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24. |
Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2. |
Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534. |
Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81. |
Arnljots, Björn et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., No. 19, 1985, pp. 211-213. |
Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221. |
Svedman, P. et al.: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133. |
K.F. Jeter, T.E. Tintle, and M. Chariker, “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246. |
G. {hacek over (Z)}ivadinović, V. ukić, {hacek over (Z)}. Maksimović, . Radak, and P. Pe{hacek over (s)}ka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164. |
F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585. |
A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967). |
M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370. |
D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery 105 (1972) pp. 511-513. |
M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I). |
C.E. Tennants, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax, ”Journal of the American Medical Association 64 (1915), pp. 1548-1549. |
Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211. |
V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”). |
V.A. Kuznetsov & N.A. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”). |
V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”). |
V.A.C.® Therapy Clinical Guidelines: A Reference Source for Clinicians (Jul. 2007). |
International Search Report and Written Opinion date mailed Aug. 19, 2011; PCT International Application No. PCT/US2011/027761. |
Number | Date | Country | |
---|---|---|---|
20110224631 A1 | Sep 2011 | US |
Number | Date | Country | |
---|---|---|---|
61312968 | Mar 2010 | US |